The imminent end of the rebate era means human resources (HR) benefits decision-makers and pharmacy consultants are about to see a paradigm shift. They will need to act quickly to adjust benefits ...
Four GOP members of the House of Representatives joined with House Democrats to force a vote on extending tax credits that ...
In today’s Pharmaceutical Executive Daily, the FDA approves a new LDL-lowering therapy, Sanofi announces two strategic deals ...
Harbour BioMed announced it has entered a multi-year, global strategic collaboration and license agreement with Bristol Myers ...
The drop reflects investors reactions to Pfizer’s new 2026 revenue forecasts, which is set to be between the range of $59.5 billion to $62.5 billion, a decline of $1.5 billion from 2025’s estimated ...
The FDA has approved GSK’s Exdensur (depemokimab-ulaa) as an add-on maintenance therapy for adolescents and adults with severe asthma characterized by an eosinophilic phenotype. 1 ...
Gabriela P. Baron ([email protected]) is a member of the New York bar and a graduate of New York University School of Law and Vassar College. She is Senior Vice President at Conduent Legal ...
Lou Pillai is the founder of Ulivmo and most recently, he was the Head of Data and Digital at Immunomedics (acquired by Gilead). Ehsan Ehsani is a director of consulting at CGI and leader of ...
In today’s Pharmaceutical Executive Daily, new analysis highlights access gaps in the TrumpRx framework, the FDA awards a ...
ADEL-Y01, a monoclonal antibody targeting tau protein, is in Phase I trials for Alzheimer's disease, developed by ADEL and ...
Lunit’s new collaboration with Daiichi Sankyo integrates AI-driven digital pathology tools into oncology translational ...
Enhertu plus Perjeta is the first new first-line treatment for HER2-positive breast cancer in over a decade, approved by the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback